Stock Market & Financial Investment News

BioMimetic says key suppliers completed FDA inspections in Q4BioMimetic Therapeutics disclosed that in Q4, all of the company’s key suppliers successfully completed FDA manufacturing inspections. The company believes the completions suggest that its suppliers "are well prepared for future Augment Bone Graft inspections, if any additional inspections are deemed necessary by the FDA." BioMimetic reiterates its previous guidance of a final approvability decision by the FDA between April 2013 and January 2014.